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Abstract
Introduction: The antigen recognition pattern of immunoglobulin M (IgM) could, when directed against protein
antigens, provide an indication of the antigenic moieties triggering new B cells. The half-life of IgM is short and
memory B cells against T-cell-dependent protein antigens typically produce IgG and not IgM antibodies. In this
study, we analyzed whether a difference exists between the fine specificity of IgM versus IgG anti-citrullinated
protein antibodies (ACPAs).
Methods: We determined the fine specificity of IgM and IgG ACPAs in 113 ACPA-positive rheumatoid arthritis
patients with IgM cyclic citrullinated peptide 2 (CCP2) levels above 100 AU/ml. Fine specificity was assessed by
performing ELISA using citrullinated peptides derived from vimentin, fibrinogen-b, fibrinogen-a and a-enolase, as
well as citrullinated proteins fibrinogen and myelin basic protein. The arginine counterparts were used as controls.
Results: Recognition of defined citrullinated antigens by IgM ACPA was confined to samples that also displayed
recognition by IgG ACPA. However, the IgM ACPA response displayed a more restricted antigen recognition profile
than IgG ACPA (OR = 0.26, P < 0.0001).
Conclusion: Our data show that several defined citrullinated antigens are recognized only by IgG ACPA, whereas
others are also recognized by IgM ACPA. These observations suggest that not all citrullinated antigens are able to
activate new B cells despite concurrent recognition by IgG ACPA.
Introduction
Anti-citrullinated protein antibodies (ACPA) may be
involved in the disease pathogenesis of rheumatoid arthri-
tis (RA). ACPA can be found early in the disease course
[1], even before disease onset [2], and the presence of
ACPA at the time of diagnosis can predict disease course
[3]. Moreover, ACPA can contribute to disease pathogen-
esis by activating immune cells [4,5] and the complement
system [6].
T h eA C P Ar e s p o n s el i k e l yr e p r e s e n t saT - c e l l - d e p e n -
dent B-cell response, given the protein nature of the
antigen recognized and the strong association with the
human leukocyte antigen shared epitope alleles. The
evolution of such a response is typically characterized by
a first wave of IgM antibodies after the first antigen con-
tact, quickly followed by the presence of IgG. After
repeated antigen exposure, the IgG responses are further
boosted while the IgM peak declines. The latter observa-
tion is explained by the presence of Ig-switched, affinity
matured, memory B cell that are formed in the presence
of CD4
+ T cells. These T cells provide the helper activ-
ity required for affinity maturation, isotype switching
and memory cell formation. When such T-cell help can-
not be provided, as in the case of hyper-IgM syndrome,
IgG, IgA and IgE antibody levels are absent or severely
reduced [7]. The presence of IgG, IgA and IgE ACPAs
[5,8], therefore, provides another line of evidence for the
T-cell-dependent nature of ACPA responses.
To the best of our knowledge, IgM-producing memory
B cells against T-cell-dependent antigens have not been
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responses against, for example, repetitive sugar residues
on bacteria [9,10]. For these reasons, it is most conceiva-
ble that the presence of IgM ACPA suggests that activa-
tion of recently recruited naïve B cells recognize
citrullinated antigens because the half-life of circulating
IgM is short. In this study, we hypothesized that there
might be certain antigens which drive the ACPA IgM
response in RA. We therefore sought to determine
whether there is a difference in the fine specificity of IgG
and IgM ACPA.
Materials and methods
Fine specificity of anticitrullinated protein antibody
immunoglobulin M
We determined the fine specificity of ACPA IgM and IgG
in 113 serum samples of anti-cyclic citrullinated peptide
(CCP2) IgG and IgM double-positive RA patients collected
from the Leiden Early Arthritis Clinic (EAC), an inception
cohort of recent-onset arthritis that was initiated at the
Department of Rheumatology at Leiden University Medi-
cal Center in 1993 [11]. We selected those patients who
had a relatively high titer of IgM CCP2 (levels ≥ 100 AU/
ml) to ensure that differences between IgG and IgM reac-
tivity could not be explained by differences in the sensitiv-
ity associated with the detection of IgG or IgM antibodies
by ELISA. For the determination of ACPA status and
ACPA levels of IgM anti-CCP2, we used a commercial
immunoassay kit (Euro-Diagnostica, Malmö, Sweden)
with minor modifications for the detection of IgM. The
collection and use of patient samples was approved by the
local medical ethics committee and in compliance with
the Declaration of Helsinki. All patients provided their
written informed consent.
Demographic data (age, gender, disease duration and
radiographic damage) of ACPA IgG-positive RA patients
who had ACPA IgM ≥ 100 AU/ml were not different
from patients displaying ACPA IgM levels < 100 AU/ml.
The peptides used in this study are linear citrulline (Cit)-
containing peptides, which are known ACPA IgG epi-
topes in RA, as well as their arginine counterparts [12].
Specifically, we used vimentin (Vim) 59 to 74: VYAT-
CitSSAVCitLCitSSVP; fibrinogen-a (Fib-a) 27 to 43:
FLAEGGGVCitGPRVVERH; Fib-b 36 to 52: NEEGFFSA-
CitGHRPLDKK; and a-enolase 5 to 20: KIHACitEIFDS-
CitGNPTV. In addition, we tested citrullinated protein
antigens (Fib and myelin basic protein (MBP)) and all of
their arginine counterparts. As described previously, the
presence of anti-Cit-MBP antibodies on ELISA is clini-
cally equivalent to the original anti-Sa (Cit-Vim) on
Western blot assays [13].
Fine specificity assays of ACPA IgG were performed
essentially as described before [12], with minor modifica-
tions for ACPA IgM [8]. In brief, for IgM-, Cit- and
arginine-containing peptides (10 μg/ml) were incubated
on streptavidin-coated plates. After being washed, sera
were incubated at 1:25 dilution at 37°C for 1 hour, bound
antibodies were detected using rabbit anti-human IgM
(Dako Denmark A/S, Glostrup, Denmark), followed by
washing with horseradish peroxidase-labeled goat anti-
rabbit IgG (Dako Denmark A/S). 2,2’-azino-bis(3-ethyl-
benzothiazoline-6-sulfonic acid) was used as a substrate,
and absorbance was determined at 415 nm. In each ELISA
plate, we included on the Cit-containing peptide eight
representative gout controls and used these to calculate
the cut-off for positivity [8]. These eight gout controls
represent a set of fifty controls as established before [8]
and were used on each plate to minimize plate-to-plate
variation. This was defined as the mean ± 2 SD of the
absorbance on the Cit-containing peptide. In addition, we
verified that the difference in absorbance between wells
coated with the Cit- and the arginine-containing peptide
was at least 0.1 as previously described [8,12]. Therefore,
sera that fulfilled both criteria were considered positive.
Stability of the anti-citrullinated protein antibody I
response
Samples from 18 patients were used to analyze the specific
reactivity of IgM against CCP2, Fib-a and Fib-b over time.
We used serum samples obtained at baseline and at 1, 2
and 5 years of follow-up. Samples were tested by ELISA as
described above. Samples were considered positive when
they displayed an absorbance value higher than the cut-off
and a difference of at least 0.1 absorbance units when
comparing the reactivity against the Cit-containing peptide
and its arginine-containing control peptide.
Statistical analysis
Differences between groups were analyzed using the
Mann-Whitney U test or analysis of variance. The associa-
tions between ACPA IgM and ACPA IgG positivity were
evaluated by using 2 × 2 tables for the estimation of ORs
and 95% CIs. The correlation between ACPA IgM and
ACPA IgG responses were determined using Spearman’s
rank-correlation coefficients. The c
2 test was used to eval-
uate differences in the frequency distribution of ACPA
IgG and IgM. All data were analyzed with GraphPad
Prism version 4.0 software (GraphPad Software, San
Diego, CA, USA) or SPSS for Windows release 16.0 soft-
ware (SPSS Inc, Chicago, IL, USA). In all tests, P <0 . 0 5
was considered significant.
Results
Anti-citrullinated protein antibody fine specificity is
different from IgG fine specificity
It has been shown that IgM ACPA can be detected in
the sera of RA patients with established disease, suggest-
ing an ongoing recruitment of new B cells into the
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Page 2 of 7ACPA response [8]. If IgM is the result of triggering of
naïve B cells, then the fine specificity of ACPA IgM
might conceivably differ from ACPA IgG, as IgM will
mainly be directed against the antigens that have
recently been detected by B cells [14]. Therefore, we
determined the ACPA IgM and IgG responses against a
set of citrullinated peptides from Fib, enolase and Vim,
as well as the responses against two citrullinated pro-
teins (Figures 1A and 1B).
Our data show that some but not all citrullinated epi-
topes are recognized by IgM ACPA (Table 1 and Figure
1B). These data indicate a restricted epitope recognition
p r o f i l eb yI g MA C P A ,a ss o m ee p i t o p e sw e r en o tr e c o g -
nized by IgM in all analyzed patient sera.
We next determined the recognition profile of IgG
ACPA. Although not all patient sera recognized all citrulli-
nated epitopes, the IgG ACPA epitope recognition pattern
was clearly much broader than the epitope recognition
profile of IgM ACPA (Figures 1A and 2). In fact, when all
ACPA reactivities were analyzed as a group, the chance of
having an IgM-positive response was four times lower
compared to IgG (OR = 0.26, P < 0.0001). For those reac-
tivities where, next to IgG ACPA, IgM ACPA responses
also were apparent, a correlation between the titers of IgG
and IgM ACPAs was observed between the positive sam-
ples (data not shown).
When reactivity patterns were directly compared at an
individual level, we observed that IgM ACPAs against
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Figure 1 The fine specificity of immunoglobulin G (IgG) and IgM anticitrullinated protein antibodies (ACPAs). The absorbance (Abs) at
415 nm of ACPA IgG (A) and IgM (B) ACPA fine specificity. ***P < 0.001. Data for gout controls from three ELISA plates are depicted. a-eno =
a-enolase; Arg = arginine; CCP2 = cyclic citrullinated peptide 2; Cit = citrulline; Fib = fibrinogen; MBP = myelin basic protein; Vim = vimentin.
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Page 3 of 7some citrullinated epitopes, but not others, were pre-
sent. However, in all cases, IgM positivity was paralleled
b yt h ep r e s e n c eo fI g Gr e c o g n i z i n gt h es a m ee p i t o p e s .
In contrast, patients can display certain IgG ACPA reac-
tivities in the absence of IgM reactivities against the
same antigen (Figure 2). Together, these data indicate
that IgM ACPAs display a more restricted antigen
recognition profiles as compared to IgG ACPAs.
Stability of the anti-citrullinated protein antibody I
response
To address the question whether the observed differences
between IgG and IgM reactivity are limited to baseline
samples only or whether they are also present at later fol-
low-up, we analyzed ACPA IgM reactivity against three
peptides over time. The reactivity of ACPA IgM against
CCP2, Fib-a and Fib-b at baseline and at 1, 2 and 5 years
of follow-up was analyzed in sera of 18 patients. We
observed that the ACPA IgM levels against these peptides
appeared rather stable (Figures 3A to 3C). Some patients
whose sera reacted with CCP2, Fib-a and Fib-b at base-
l i n em a yo v e rt i m eb e c o m eI g M - n e g a t i v e( F i g u r e3 D ) .
Importantly, none of the patients tested became IgM-ser-
opositive against either Fib-a or Fib-b peptides. These
data indicate that the observations made using the base-
line samples (Figures 1 and 2) would also be made at any
of the follow-up time points. Collectively, these data
t h e r e f o r ei n d i c a t et h a tt h eA C P AI g Mr e s p o n s ei sn a r -
rower than the ACPA IgG response, an observation not
applicable only to the baseline results but also during fol-
low-up.
Discussion
In this study, we observed that ACPA IgM responses are
different from ACPA IgG responses, as they display a
more restricted antigen recognition pattern. These data
are intriguing, as they indicate that the regulation of the
IgM ACPA response differs from the regulation of B cells
producing IgG-directed against citrullinated antigens.
Although the reason for this difference is not known, we
think it is most conceivable that these findings are
explained by a limited recruitment of new B cells into the
ACPA response that is driven by some, but not other,
citrullinated antigens. Given the short half-life of circulat-
ing IgM and the lack of memory B cells producing IgM
CCP
vim
Fib-Į
IgG Fib-ȕ
Į-eno
Fib
MBP
CCP
vim
Fib-Į
IgM Fib-ȕ
Į-eno
Fib
MBP
Figure 2 Positivity of immunoglobulin G (IgG) and IgM anticitrullinated protein antibodies (ACPAs). The citrullinated epitopes recognized
by IgG and IgM ACPAs in each individual. The gray area represents positive reactivity, and the white area represents lack of reactivity. a-eno =
a-enolase; CCP = cyclic citrullinated peptide; Fib = fibrinogen; MBP = myelin basic protein; Vim = vimentin.
Table 1 Specific positivity of anticitrullinated protein
antibody immunoglobulin G and immunoglobulin M in
113 rheumatoid arthritis patients directed against a set
of defined specificities
Epitope IgG (%) IgM (%)
CCP2 100 100
Vim 56 7
Fib-a 33 4
Fib-b 94 40
a-enolase 55 8
Fib 53 40
MBP 63 40
CCP2 = cyclic citrullinated peptide 2; Fib = fibrinogen; IgG = immunoglobulin
G; IgM = immunoglobulin M; MBP = myelin basic protein; Vim = vimentin.
Suwannalai et al. Arthritis Research & Therapy 2011, 13:R195
http://arthritis-research.com/content/13/6/R195
Page 4 of 7against protein antigens, we think that the IgM ACPAs
detected in this study are produced by new B cells that are
recruited into the ACPA response against certain citrulli-
nated antigens. Even in the case where ACPA IgM-produ-
cing memory B cells exist, it is still interesting that such
cells are present only against certain citrullinated antigens.
For this study, we selected patients who are double-posi-
tive for IgG and IgM CCP2 reactivity. To exclude the pos-
sibility that differences between IgG and IgM may be
explained by differences in the sensitivity associated with
the detection of IgG or IgM antibodies by ELISA, we
selected only patients with an IgM level of at least 100
AU/ml. Indeed, in the setup we used, we observed that,
although the IgG responses against the different citrulli-
nated antigens were rather similar in absorbance units,
IgM reactivity was detected only against some antigens
but not others. This observation was made at baseline but
appears also to be present at follow-up. To ensure that we
did not introduce additional bias into our data, we com-
pared the demographic data (age, gender, disease duration
and radiographic damage) of ACPA IgG-positive RA
patients who had ACPA IgM ≥ 100 AU/ml with those
who had ACPA IgM < 100 AU/ml and observed no
differences.
Since IgM rheumatoid factor (RF) could also be a con-
founding factor, we compared RF levels between the
patients who displayed ACPA IgM ≥ 100 AU/ml with
those who had ACPA IgM < 100 AU/ml and observed
that in RA patients with ACPA IgM ≥ 100 AU/ml, the
levels of RF IgM were higher than in RA patients who had
ACPA IgM < 100 AU/ml (RF IgM 50 AU/ml (25 to 118)
and 28 AU/ml (12 to 60), respectively). To exclude the
possibility that our findings were influenced by IgM RF,
we analyzed ACPA IgM specificities in relation to IgM RF.
We observed that IgM RF-positive samples can be nega-
tive for IgM ACPA reactivities and that, in the absence of
IgM RF, IgM ACPA reactivities can be detected readily
(data not shown). RF-positive samples that have IgG reac-
tivity against all fine specificity epitopes may have IgM
ACPA against only some antigens and not others, con-
firming that our assay did not merely detect IgM RF. Pre-
viously, we addressed this issue experimentally [8]. When
RFs were depleted from RF IgM-positive, ACPA IgM-posi-
tive and ACPA IgG-positive sera using IgG-coated
IgM tested pos BL  neg FU pos FU
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Figure 3 Stability of the immunoglobulin M anticitrullinated protein antibody response. Sera taken from 18 patients at baseline (BL) and
at 1, 2 and 5 years of follow-up were analyzed by ELISA for reactivity against cyclic citrullinated peptide 2 (CCP2), fibrinogen (Fib)-a and Fib-b.
(A) through (C) Graphs displaying the immunoglobulin M (IgM) reactivity to the indicated peptides over time. The absorbance of citrulline (cit)
reactivity minus absorbance of the arginine (arg) reactivity is shown. (D) Table showing the number of positive patients at baseline (BL) as well
as the conversion toward negative or positive during one of the follow-up (FU) time points analyzed.
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Page 5 of 7Cyanogen bromide-activated-Sepharose beads (Sigma-
Aldrich, St Louis, MO, USA), there was no reduction of
ACPA IgM levels. Moreover, after mixing sera which were
highly positive for RF IgM but negative for ACPA IgG and
ACPA IgM with sera which were RF IgM- and ACPA
IgM-negative but ACPA IgG-positive, ACPA IgM could
not be detected [8]. Collectively, these observations sup-
port the notion that true IgM ACPA and not IgM RF
bound to ACPA IgG were detected by the methods
employed.
Although it is tempting to speculate, these studies
should not be taken as an argument for the involvement
of the antigens analyzed here in the recruitment of new B
cells into the ACPA response. Peptides are unlikely to
reflect correctly the three-dimensional structure of citrulli-
nated proteins that form the epitope for antibodies. More-
over, ACPA IgG is cross-reactive to multiple citrullinated
antigens [15,16], and therefore recognition of a citrulli-
nated antigen by ACPA IgG does not indicate that this
antigen is necessarily involved in the induction of B-cell
responses. Nonetheless, our data do show that the IgM
ACPA response is significantly more restricted than that
of the IgG ACPA present in the same patient.
How IgM can be formed in the presence of an active
I g Gr e s p o n s ea g a i n s tt h es a m ea n t i g e ni sn o tc l e a r .I n
other situations, as exemplified by the prophylactic
administration of anti-Rhes u sDa n t i g e na n t i b o d i e st o
pregnant women carrying a Rhesus D-positive child, the
presence of IgG against a certain antigen will prevent the
induction of a novel IgM response. The mechanism
behind this protective measure is thought to be mediated
by either the capture and clearance of circulating Rhesus
D antigen and/or by IgG-Rhesus D immune complexes
that inactivate new Rhesus D-reactive B cells through
FcgRIIB, the inhibitory Fcg IIB receptor [17]. Clearly, IgG
ACPAs do not inhibit the activation of IgM-positive,
citrullinated antigen-reactive B cells. The reason for this
finding is not known but could possibly be explained by
the low avidity of the ACPA [18], conceivably resulting in
“nonstable” immune complexes unable to trigger
FcgRIIB.
Conclusions
Collectively, our data show that the immune response
against one citrullinated antigen is different from the
immune response against another citrullinated protein.
Some responses are dominated by IgG, whereas both
IgM and IgG responses were found for other ACPA
antigens. Elucidation of the mechanism behind this
observation could be of relevance to the identification of
those citrullinated antigens that drive ACPA responses
and could provide clues to how the continuous recruit-
ment of new B cells can be halted.
Abbreviations
ACPA: anticitrullinated protein antibody; Arg: arginine; AU: arbitrary unit; BL:
baseline; Cit: citrulline; CCP2: cyclic citrullinated peptide 2; EAC: Early Arthritis
Clinic; ELISA: enzyme-linked immunosorbent assay; Fib: fibrinogen; FU:
follow-up; Ig: immunoglobulin; IgM: immunoglobin M LUMC: Leiden
University Medical Center; MBP: myelin basic protein; RA: rheumatoid
arthritis; RF: rheumatoid factor.
Acknowledgements
PS received a grant from Ramathibodi Hospital, Mahidol University, Bangkok,
Thailand. AW is supported by the Dutch Organization for Scientific Research
(AGIKO grant). REMT is a recipient of a NWO-VICI grant, and LAT is a
recipient of a NWO-VENI grant. This study was supported by the European
Union (Sixth Framework Programme integrated project Autocure and
Seventh Framework Programme integrated project Masterswitch 223404) as
well as IMI-BTCure. This study was also supported by national funding from
The Netherlands Genomics Initiative (NGI) as part of The Netherlands
Proteomics Center (NPC) and the Center for Medical Systems Biology
(CMSB).
Author details
1Department of Rheumatology, Leiden University Medical Center (LUMC), PO
Box 9600, NL-2300 RC Leiden, The Netherlands.
2Department of
Immunohematology and Blood Tranfusion, PO Box 9600, NL-2300 RC Leiden
University Medical Center (LUMC), Leiden, The Netherlands.
Authors’ contributions
PS, TWJH, REMT and LAT conceived the study and participated in its design
and edited the manuscript. PS and LAT drafted and prepared the
manuscript and performed the statistical analyses. AW assisted with
manuscript preparation. PS, LVT, GSR and NL performed blood analyses. JWD
provided peptides essential for the assays. All authors contributed to the
interpretation of the study findings and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 5 July 2011 Revised: 14 October 2011
Accepted: 30 November 2011 Published: 30 November 2011
References
1. van Venrooij WJ, Hazes JM, Visser H: Anticitrullinated protein/peptide
antibody and its role in the diagnosis and prognosis of early
rheumatoid arthritis. Neth J Med 2002, 60:383-388.
2. Nielen MM, van der Horst AR, van Schaardenburg D, van der Horst-
Bruinsma IE, van de Stadt RJ, Aarden L, Dijkmans BA, Hamann D:
Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and
prognostic value in early arthritis. Ann Rheum Dis 2005, 64:1199-1204.
3. Lindqvist E, Eberhardt K, Bendtzen K, Heinegård D, Saxne T: Prognostic
laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum
Dis 2005, 64:196-201.
4. Clavel C, Nogueira L, Laurent L, Iobagiu C, Vincent C, Sebbag M, Serre G:
Induction of macrophage secretion of tumor necrosis factor α through
Fcγ receptor IIa engagement by rheumatoid arthritis-specific
autoantibodies to citrullinated proteins complexed with fibrinogen.
Arthritis Rheum 2008, 58:678-688.
5. Schuerwegh AJ, Ioan-Facsinay A, Dorjée AL, Roos J, Bajema IM, van der
Voort EI, Huizinga TW, Toes RE: Evidence for a functional role of IgE
anticitrullinated protein antibodies in rheumatoid arthritis. Proc Natl Acad
Sci USA 2010, 107:2586-2591.
6. Trouw LA, Haisma EM, Levarht EW, van der Woude D, Ioan-Facsinay A,
Daha MR, Huizinga TW, Toes RE: Anti-cyclic citrullinated peptide antibodies
from rheumatoid arthritis patients activate complement via both the
classical and alternative pathways. Arthritis Rheum 2009, 60:1923-1931.
7. Kroczek RA, Graf D, Brugnoni D, Giliani S, Korthüer U, Ugazio A, Senger G,
Mages HW, Villa A, Notarangelo LD: Defective expression of T-cell CD40
ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993,
361:539-541.
8. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, Ioan-
Facsinay A, Drijfhout JW, van Tol MJ, Breedveld FC, Huizinga TW, Toes RE:
Suwannalai et al. Arthritis Research & Therapy 2011, 13:R195
http://arthritis-research.com/content/13/6/R195
Page 6 of 7Isotype distribution of anti-cyclic citrullinated peptide antibodies in
undifferentiated arthritis and rheumatoid arthritis reflects an ongoing
immune response. Arthritis Rheum 2006, 54:3799-3808.
9. Rajewsky K: Clonal selection and learning in the antibody system. Nature
1996, 381:751-758.
10. Racine R, McLaughlin M, Jones DD, Wittmer ST, MacNamara KC,
Woodland DL, Winslow GM: IgM production by bone marrow
plasmablasts contributes to long-term protection against intracellular
bacterial infection. J Immunol 2011, 186:1011-1021.
11. van Aken J, van Dongen H, le Cessie S, Allaart CF, Breedveld FC,
Huizinga TW: Comparison of long term outcome of patients with
rheumatoid arthritis presenting with undifferentiated arthritis or with
rheumatoid arthritis: an observational cohort study. Ann Rheum Dis 2006,
65:20-25.
12. Verpoort KN, Cheung K, Ioan-Facsinay A, van der Helm-van Mil AH, de
Vries-Bouwstra JK, Allaart CF, Drijfhout JW, de Vries RR, Breedveld FC,
Huizinga TW, Pruijn GJ, Toes RE: Fine specificity of the anti-citrullinated
protein antibody response is influenced by the shared epitope alleles.
Arthritis Rheum 2007, 56:3949-3952.
13. Boire G, Cossette P, de Brum-Fernandes AJ, Liang P, Niyonsenga T, Zhou ZJ,
Carrier N, Daniel C, Ménard HA: Anti-Sa antibodies and antibodies against
cyclic citrullinated peptide are not equivalent as predictors of severe
outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther
2005, 7:R592-R603.
14. Bernasconi NL, Traggiai E, Lanzavecchia A: Maintenance of serological
memory by polyclonal activation of human memory B cells. Science 2002,
298:2199-2202.
15. Ioan-Facsinay A, el-Bannoudi H, Scherer HU, van der Woude D, Ménard HA,
Lora M, Trouw LA, Huizinga TW, Toes RE: Anti-cyclic citrullinated peptide
antibodies are a collection of anti-citrullinated protein antibodies and
contain overlapping and non-overlapping reactivities. Ann Rheum Dis
2011, 70:188-193.
16. Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K,
Engström A, Venables PJ, Lundeberg J, Holmdahl R, Klareskog L,
Malmström V: Multiple antibody reactivities to citrullinated antigens in
sera from patients with rheumatoid arthritis: association with HLA-DRB1
alleles. Ann Rheum Dis 2009, 68:736-743.
17. Kumpel BM: In vivo studies of monoclonal anti-D and the mechanism of
immune suppression. Transfus Clin Biol 2002, 9:9-14.
18. Suwannalai P, Scherer HU, van der Woude D, Ioan-Facsinay A, Jol-van der
Zijde CM, van Tol MJ, Drijfhout JW, Huizinga TW, Toes RE, Trouw LA: Anti-
citrullinated protein antibodies have a low avidity compared with
antibodies against recall antigens. Ann Rheum Dis 2011, 70:373-379.
doi:10.1186/ar3524
Cite this article as: Suwannalai et al.: The fine specificity of IgM anti-
citrullinated protein antibodies (ACPA) is different from that of IgG
ACPA. Arthritis Research & Therapy 2011 13:R195.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Suwannalai et al. Arthritis Research & Therapy 2011, 13:R195
http://arthritis-research.com/content/13/6/R195
Page 7 of 7